Request Demo
Last update 29 Nov 2025
HSK-42360
Last update 29 Nov 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms HSK42360-Na, HSK42360 |
Target |
Action inhibitors |
Mechanism BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with HSK-42360NCT07158710
A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HSK42360 in Pediatric Patients With BRAF V600-Mutant Malignant Brain Tumors
NCT06536400
A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of HSK42360 in Patients With BRAF V600 Mutation Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with HSK-42360
Login to view more data
100 Translational Medicine associated with HSK-42360
Login to view more data
100 Patents (Medical) associated with HSK-42360
Login to view more data
100 Deals associated with HSK-42360
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma Harboring BRAF V600 Mutation | Phase 1 | China | 15 Aug 2025 | |
| BRAF V600 mutation-positive brain cancer | Phase 1 | China | 06 Aug 2025 | |
| BRAF mutation Solid Tumors | Phase 1 | China | 25 Jun 2024 | |
| Brain Cancer | Phase 1 | China | 25 Jun 2024 | |
| Brain metastases | Phase 1 | China | 25 Jun 2024 | |
| Central Nervous System Neoplasms | Phase 1 | China | 25 Jun 2024 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 25 Jun 2024 | |
| BRAF V600 mutation-positive Neoplasms | Phase 1 | China | 21 Jun 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | BRAF mutation Solid Tumors BRAF V600 mutations | 17 | vrgkhldbrf(ouuizxsptq) = increased creatinine and increased ALT etiqtjtwog (jbzsjjsvuu ) View more | Positive | 30 May 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free